Thyroid hormones and the risk of NAFLD | Thyroid hormones and the risk of progressive liver fibrosis | when NFS < 0.676, FT4 and the risk of NAFLD | |||||||
---|---|---|---|---|---|---|---|---|---|
OR | 95%CI | p value | OR | 95%CI | p value | OR | 95%CI | p value | |
FT3 | |||||||||
Model 1 | 1.489 | 1.059–2.094 | 0.022* | 0.532 | 0.334–0.846 | 0.008** | |||
Model 2 | 1.456 | 1.029–2.058 | 0.034* | 0.56 | 0.35–0.899 | 0.016* | |||
Model 3 | 1.041 | 0.7–1.549 | 0.842 | ||||||
Model 4 | 0.654 | 0.363–1.176 | 0.156 | ||||||
FT4 | |||||||||
Model 1 | 0.86 | 0.77–0.96 | 0.007** | 0.798 | 0.679–0.937 | 0.006** | 0.859 | 0.761–0.969 | 0.014* |
Model 2 | 0.857 | 0.767–0.957 | 0.006** | 0.802 | 0.683–0.942 | 0.007** | |||
Model 3 | 0.865 | 0.762–0.982 | 0.026* | ||||||
Model 4 | 0.796 | 0.655–0.967 | 0.022* | ||||||
Model 5 | 0.856 | 0.758–0.968 | 0.013* | ||||||
Model 6 | 0.801 | 0.672–0.955 | 0.013* | ||||||
TT3 | |||||||||
Model 1 | 2.171 | 1.025–4.602 | 0.043* | 0.142 | 0.047–0.431 | 0.001*** | |||
Model 2 | 2.095 | 0.985–4.457 | 0.055 | 0.152 | 0.05–0.464 | 0.001*** | |||
Model 3 | 1.166 | 0.495–2.726 | 0.726 | ||||||
Model 4 | 0.151 | 0.038–0.597 | 0.007** | ||||||
TT4 | |||||||||
Model 1 | 0.985 | 0.97–1.0 | 0.047* | ||||||
Model 2 | 0.984 | 0.969–0.999 | 0.033* | ||||||
Model 4 | 0.98 | 0.962–1.0 | 0.046* | ||||||
TSH | |||||||||
Model 1 | 1.252 | 1.016–1.544 | 0.035* | ||||||
Model 2 | 1.224 | 0.99–1.513 | 0.062 | ||||||
Model 4 | 1.13 | 0.884–1.446 | 0.33 | ||||||
FT3/FT4 | |||||||||
Model 1 | 2870.6 | 59.9–137,433.9 | 0.000*** | 2023.8 | 27.3–150,045.9 | 0.001*** | |||
Model 2 | 2493.8 | 50.9–122,059.1 | 0.000*** | ||||||
Model 3 | 99.0 | 1.3–7567.3 | 0.038* | ||||||
Model 5 | 1395.9 | 17.9–108,303.0 | 0.001*** | ||||||
Model 6 | 7545.9 | 18.4–3,093,672.6 | 0.004*** |